Tryptamine Therapeutics Limited (ASX: TYP) is sharpening its position in the psychedelic medicine sector with continued progress across its precision psilocin program. Focused on treating eating disorders and chronic pain, the company’s lead formulation, TRP-8803, is designed to overcome the shortcomings of oral psilocybin by delivering precision dosing, rapid onset, and a treatment model built for commercial scalability.